ArticleFrontiers in medicine2025
Lutein-based dye vitrectomy for idiopathic epiretinal membrane: a pilot study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chromovitrectomy: current evidence, emerging technologies, and practical applications in vitreoretinal surgery.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The use of vital dyes is essential for enhancing visualization of the vitreous and vitreoretinal interface during surgery. In this study, we evaluated the efficacy of a new lutein-based vital dye (LB-VD) for selective staining of the vitreous body and posterior hyaloid in patients undergoing 25 G vitrectomy for idiopathic epiretinal membrane (ERM). Methods: A total of 18 patients who underwent ERM surgery assisted by LB-VD were retrospectively analyzed. The surgeon completed a postoperative satisfaction questionnaire to evaluate the vitreous staining. Data on best-corrected visual acuity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), and fixation stability were collected at baseline and at 4 and 6 months post-surgery. Results: LB-VD effectively stained the vitreous body and posterior hyaloid, facilitating key surgical maneuvers. Significant improvements were observed in BCVA and CRT at both 4 and 6 months post-surgery. Specifically, BCVA improved from 0.60 ± 0.29 LogMAR at baseline to 0.33 ± 0.26 LogMAR at 4 months ( Discussion: LB-VD provided clear visualization of the vitreous body and posterior hyaloid, thereby facilitating key vitreoretinal surgical tasks. These findings suggest that LB-VD is an effective and safe alternative to traditional dyes currently used in vitreoretinal surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.